Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Shares Pass Above Fifty Day Moving Average – Here’s Why

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $28.35 and traded as high as $30.86. Lakefront Biotherapeutics American Depositary Shares shares last traded at $30.58, with a volume of 156,201 shares trading hands.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Zacks Research upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research note on Monday, June 8th. Wall Street Zen cut shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $36.50.

Lakefront Biotherapeutics American Depositary Shares Trading Up 0.8%

The stock has a 50 day moving average of $28.35 and a 200-day moving average of $30.89. The company has a market capitalization of $2.02 billion, a P/E ratio of -21.69 and a beta of 0.25.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of ($1.27) by $1.52. The firm had revenue of $8.75 million for the quarter, compared to the consensus estimate of $11.26 million. As a group, sell-side analysts expect that Lakefront Biotherapeutics American Depositary Shares will post -6.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LKFT. State of Wyoming purchased a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the second quarter worth $28,000. Van ECK Associates Corp grew its stake in Lakefront Biotherapeutics American Depositary Shares by 61.6% during the fourth quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 750 shares in the last quarter. Arax Advisory Partners increased its holdings in Lakefront Biotherapeutics American Depositary Shares by 319.2% in the 4th quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 1,778 shares during the last quarter. Quadrant Capital Group LLC bought a new stake in Lakefront Biotherapeutics American Depositary Shares in the 3rd quarter valued at $134,000. Finally, Squarepoint Ops LLC purchased a new stake in Lakefront Biotherapeutics American Depositary Shares in the 3rd quarter worth $211,000. 32.46% of the stock is currently owned by institutional investors.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.